A multicentric, randomized, controlled phase III study of centhaquine (Lyfaquin ® ) as a resuscitative agent in hypovolemic shock patients.
Anil GulatiRajat ChoudhuriAjay GuptaSaurabh SinghS K Noushad AliGursaran Kaur SidhuParvez David HaquePrashant RahateAditya R BothraG P SinghSanjeev MaheshwariDeepak JeswaniSameer HaveriApurva AgarwalNilesh Radheshyam AgrawalPublished in: medRxiv : the preprint server for health sciences (2021)
A multicentric, randomized, controlled trial was conducted to evaluate the efficacy of centhaquine in hypovolemic shock patients.One hundred and five patients were randomized 2:1 to receive centhaquine or saline. Centhaquine was administered at a dose of 0.01 mg/kg in 100 mL saline and infused over 1 hour. The control group received 100 mL of saline over a 1-hour infusion.Centhaquine improved blood pressure, shock index, reduced blood lactate levels, and improved base deficit. Acute Respiratory Distress Syndrome (ARDS) and Multiple Organ Dysfunction Syndrome (MODS) score improved with centhaquine.An 8.8% absolute reduction in 28-day all-cause mortality was observed in the centhaquine group. There were no drug-related adverse events in the study.
Keyphrases
- end stage renal disease
- blood pressure
- acute respiratory distress syndrome
- randomized controlled trial
- phase iii
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- low dose
- extracorporeal membrane oxygenation
- mechanical ventilation
- oxidative stress
- systematic review
- intensive care unit
- type diabetes
- patient reported outcomes
- adipose tissue
- heart rate
- insulin resistance
- patient reported